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ABSTRACT 
Hanoor Sharma. M.S. Department of Microbiology and Immunology, Wright State    
University, 2016. Identification of Protein-Protein Interactions of Amyotrophic Lateral 
Sclerosis Associated Protein TDP-43. 
 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease caused by progressive 
degeneration of upper and lower motor neurons in the brain and spinal cord. Multiple 
mutations are found in some of the proteins associated with ALS, including superoxide 
dismutase (SOD1), fused in sarcoma (FUS) and trans-activation response DNA-binding 
protein (TDP-43). TDP-43 is a DNA and RNA binding protein, well conserved, and 
ubiquitously expressed in all tissues. TDP-43 resides in the nucleus and sometimes shuttles 
between nucleus and cytoplasm. Mutations in TDP-43 leads to mislocalization of TDP-43 
to the cytosol where it was ubiqutinated and hyperphosphsorylated, ultimately leading to 
neuronal cell death. The aim of this project is to identify and compare binding partners of 
both wild type (WT) and mutant TDP-43 using yeast two hybrid screening (Y2H). We 
identified PICK1 (Protein interacting with protein C-kinase) that binds to both wild type 
and disease causing mutant (M337V) TDP-43.  Interestingly, PICK1 also interacts with 
other TDP-43 mutants (D169G, Q331K, G298S, and A315T), although the affinity of 
interaction is weaker.  
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INTRODUCTION AND BACKGROUND 
Amyotrophic Lateral Sclerosis (ALS)  
                ALS is a neurodegenerative disease resulting from the progressive 
degeneration of upper and lower motor neurons in the spinal cord, brainstem and motor 
cortex (Rothstein, 2009) and is particularly devastating due to its rapid rate of progression 
and lethality. ALS has two forms, sporadic and familial. Sporadic ALS is spontaneous and 
affects 90 percent of patients while familial form is hereditary and affects 10 percent of 
ALS patients. The main symptoms of ALS are muscle atrophy and spasticity, difficulty in 
speaking (dysarthria), swallowing (dysphagia), and breathing (dyspnea). Individuals 
affected by ALS ultimately lose the ability to initiate and control all voluntary movement, 
although bladder and bowel sphincters and the muscles responsible for eye movement are 
usually, but not always, spared until the final stages of the disease. Ultimately respiratory 
failure results in death of ALS patients within three to five years from the onset of 
symptoms (Johnston et al., 2006). ALS can affect people of any age but usually strikes late 
middle age people. A pathological hallmark of ALS is ubiquitin-positive inclusions 
composed of misfolded proteins found in neuronal and glial cells (Johnston et al., 2006), 
but it’s still unclear if these inclusions cause the disease. Despite major research efforts, 
the cause of ALS is unknown and no cure currently exists. Several mechanism including 
cytoskeleton abnormalities, protein instability, protein aggregation, and impairment of 
proteasomes have been proposed but the exact mechanism and why cell death is specific 
to motor neurons remains elusive. Multiple mutations in a variety of proteins have been 
implicated in ALS including Superoxide dismutase 1 (SOD1), Fused in sarcoma (FUS), 
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Senataxin (SETX), chromosome 9 open reading frame 72 (C9ORF72) and Trans-activation 
response DNA-binding protein (TDP-43).  
 
TDP- 43 
  TDP-43 is a 414-amino acid DNA and RNA binding protein that is highly 
conserved and ubiquitously expressed. It was identified as one of the proteins responsible 
for ALS (Neumann et al., 2006). TDP-43 is encoded by the TARDBP gene located on 
chromosome 1 (Neumann et al., 2006) and contains two RNA recognition motifs (RRM1 
and RRM2), a nuclear export signal (NES) within RRM2, a nuclear localization sequence 
(NLS) in the N terminus and a C-terminal glycine-rich domain (Figure 1; Fuentealba, et 
al., 2010). The RRMs are involved in RNA stabilization and processing, while the NES 
allows the export of TDP-43 from the nucleus to the cytoplasm and the NLS is involved in 
the import of TDP-43 into the nucleus. The C-terminal is the region where most of the 
protein-protein interactions take place (Guo et al., 2011). Interestingly, this is also the 
region where most of the ALS-linked mutations were identified.  
TDP-43 is an important component of the Drosha complex, a class II RNase 
enzyme responsible for initiating the processing of microRNA in the nucleus (Figure 2a) 
(Ling et al., 2010). TDP-43 functions in binding to heterogeneous nuclear 
ribonucleoprotein (hnRNP) and regulates splicing of pre-mRNA species (Figure 2b). TDP-
43 also functions to silence the promoter sequence of single stranded DNA (ssDNA), 
resulting in transcriptional repression (Figure 2c). In cytoplasm, TDP-43 protects mRNAs 
from stress conditions by forming stress granules (Figure 2d) (Edwards et al., 2013).   
 
hnRNP A/B 
binding 
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Figure 1: Structural domains of TDP-43. A schematic of TDP-43 protein shows the two RNA recognition 
motifs (RRM1 and RRM2, purple and blue respectively), NES (green), NLS (red) and glycine rich domain 
(yellow) (Adapted from Carlomagno et al.,  2014). 
. 
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TDP-43 also plays a role in the translocation of mRNA granules from the nucleus to the 
cytoplasm (Figure 2e). TDP-43 binds to a 3′ untranslated region of mRNA that stabilizes 
the mRNA in the cytoplasm (Figure 2f). TDP-43 is essential for the early development of 
embryo. Studies have shown that the expression of the TDP-43 gene leads to healthy 
embryonic development of mice; whereas the absence of TDP-43 is lethal (Sephton et al., 
2012).   
 
Mislocalization of TDP-43 
More than 30 mutations have been identified in TDP-43 associated with ALS 
(Herskowitz et al., 2012). Mutations, in most cases, lead to the protein mislocalization and 
aggregation in the cytosol, which is toxic to neuronal cells (Barmada et al., 2010, Guo et 
al., 2011, Benajiba et al., 2009, Chen-Plotkin et al., 2010; Figure 3). Although exact 
mechanism is still unknown, it has been proposed that loss of function of TDP-43 in 
nucleus and a gain of toxicity in cytosol may result in neurodegeneration in ALS patients 
(Kabashi et al., 2011). 
 
TDP-43 interactions 
TDP-43, shuttling between nucleus and cytosol, has been reported to interact with 
proteins both in nucleus and cytosol. One of the cytoplasmic proteins that interact with 
TDP-43 is polyadenylate binding protein-1 (PABPC-1), a RNA binding protein that 
stabilizes poly (A) mRNA and regulates protein translation (Bernstein et al., 1989). 
PABPC-1 strongly interacts with TDP-43 and this interaction is RNA dependent, because 
the binding between TDP-43 and PABPC-1 is diminished when the interaction is treated 
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Figure 2: Biological functions of TDP-43 in nucleus and cytoplasm. In the nucleus, TDP-43 functions to 
a. process primary microRNA along with drosha b. regulate spicing of pre-mRNA species along with hnRNP. 
and c. act as a transcriptional repressor. In the cytoplasm, TDP-43 a. protects mRNA under condition of 
stress. b. stabilizes mRNA. and c. assists in nucleo-cytoplasmic shuttling of mRNA. (Adapted from Edwards 
et al., 2013).     
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Figure 3: TDP-43 under normal and disease conditions. a.TDP-43 normally resides in the nucleus and 
regulates gene expression and pre-mRNA splicing b. Mutated TDP-43 leaves the nucleus, accumulates in the 
cytoplasm where it is ubiquitinated, hyperphosphorylated, cleaved (Chen-Plotkin et al., 2010)      
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with RNase enzyme (Freibaum et al., 2010; Table 1). In nucleus, TDP-43 interacts with 
heterogeneous nuclear ribonucleoprotein (hnRNP). hnRNP plays important function in 
regulating splicing activity and in transport of mRNA out of nucleus (Buratti, 2005) (Table 
1).  
There are other proteins that interact with TDP-43. Nucleus Accumbens 1 (NAC1), 
is a member of the family of repressor proteins, that are involved in transcriptional 
repression (Ahmad et al., 2003) and actin cytoskeleton regulation of neurons (Kang et al., 
2004). The actin cytoskeleton regulation helps in morphological development of neurons 
(Luo et al., 2002). This study showed that NAC1 interacts with WT TDP-43 in the nucleus. 
When treated with glutamate, NAC1, TDP-43, and proteasome colocalizes together into 
the cytoplasm, resulting in death of motor neurons (Scofield et al., 2012) (Table 1). 
Therefore NAC-1 may play a role in cytoplasmic mislocalization and degradation of 
proteins in the neurons of patients suffering from ALS. 
Amyloid precursor protein (APP), a type 1 membrane protein when treated with β 
secretase, APP is cleaved into toxic amyloid β peptide and intracellular domain of APP 
called AICD. WT TDP-43 was shown to interact with AICD in nucleus (Table 1). 
Overexpression of TDP-43 enhanced AICD-induced p53 transcription (a tumor suppressor 
protein) and apoptosis, ultimately resulting in death of Hela cells by arresting p53, 
demonstrating that abnormal TDP-43 and AICD interactions may lead to cell death (Wang 
et al., 2014). Fused in sarcoma (FUS) is another RNA binding protein that is involved in 
ALS (Verbeeck et al., 2012). Some of the mutant TDP-43 has been shown to have an 
increased interaction with FUS in the nucleus (Michaeline et al., 2013). Mutant TDP-43 
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also promotes posttranslational modifications such as phosphorylation and ubiquitination 
of FUS (Lagier-Tourenne et al., 2010). (Table 1). 
Although the detailed mechanism of TDP-43 involvement with the disease remains 
unclear, much of TDP43 function has been learned from studying its binding partners. So 
far, protein interaction studies were overwhelmingly performed on the WT TDP-43, and 
little was dedicated to the disease causing mutant proteins.   
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Table 1: Known Protein-Protein Interactions with TDP-43. The table shows proteins that interact with 
TDP-43, their functions and the role of their interactions (Co-IP: co- immunoprecipitation) 
 
 
Gene 
 
 
 
Protein 
 
 
Protein 
Function 
 
 
Role of 
Interactions 
 
Detection 
method 
 
References 
 
PABPC 1 
 
Polyadenylate-
binding protein -1 
 
Stabilizes mRNA 
and RNA 
dependent 
 
Unknown 
 
Co-IP 
 
Freibaum 
et al., 2010 
 
 
hnRNP 
 
Heterogeneous 
nuclear 
ribonucleoprotein 
 
 
Splicing and 
Transport mRNA 
out of nucleus  
 
Inhibits splicing 
activity 
 
Pull-down 
 
Buratti et 
al., 2005 
 
NAC1 
 
Nucleus Accumbens1 
 
Repression of 
transcription 
factors 
Degradation of 
protein in the 
presence of  
glutamate 
 
Co-IP 
 
Scofield et 
al., 2012 
 
AICD 
 
Amyloid Precursor 
Protein Intracellular 
Domain 
 
Not known 
 
Apoptosis  
 
Co-IP 
 
Wang et 
al., 2014 
 
FUS 
 
Fused in sarcoma 
 
Regulates 
transcription, 
mRNA splicing 
and DNA repair 
 
Formation of 
aggregates 
 
Co-IP 
 
Ling et al., 
2010 
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HYPOTHESIS 
 
I hypothesize that binding partners of WT and the mutant form of TDP-43 are 
different. The mutant protein’s loss of normal interaction or gain of abnormal interaction 
may help to understand why the mutant protein is malignant to the cell.  
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SPECIFIC AIMS 
 
Aim 1: To identify proteins that interact with WT TDP-43 
Previous protein interaction studies on WT TDP-43 have been done using pull 
down assays followed by western blotting or mass spectrometry. Here I used Y2H, a 
genetic approach widely used to identify protein-protein interactions. Due to 
complementarity of the different methods, I expect to identify new interactions for TDP-
43. The cDNA libraries of the brain and the fetal brain were used to check if the interactions 
of TDP-43 differ at various stages of life.  
 
Aim 2: To identify proteins interacting with mutant TDP-43 
My second aim will use the same Y2H method as above, with the focus on TDP-
43 mutants commonly found in ALS patients, including D169G, G298S, A315T, Q331K 
and M337V. The rational for choosing these mutants are: firstly, these five mutants of 
TDP-43 are commonly found in ALS patients; secondly, these mutants cover both sporadic 
and familial cases (D169G and Q331K in sporadic while G298S, A315T and M337V in 
familial cases); Lastly, these mutants were selected from different parts of protein: D169G 
in RRM1 domain and G298S, A315T, Q331K and M337V from C- terminus of the protein, 
where the most mutations were identified (Figure 4).  
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Figure 4: ALS associated TDP-43 mutations. Most of the TDP-43 mutations are found in C terminal region 
of TDP-43. Those highlighted in red are the mutated residues and X in green represents the truncated mutant. 
The mutants chosen for this project are circled in blue  (sporadic: D169G and Q331K) and in red  
(familial: G298S, A315T and M337V) (Buratti et al., 2009).   
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METHODS AND MATERIALS 
PCR amplification of TDP-43 
Full length WT TDP-43 was amplified from pRS426 Gal1/TDP-43 by PCR using 
forward primer 5’ GGGGACAACTTTGTACAAAAAAGTTGGC 3’ and reverse primer 
5’ GGGGACAACTTTGTACAAGAAAGTTGA 3’. The forward and reverse primers 
include gateway cloning sites (attB1 and attB2) respectively. The amplification protocol 
consisted of an initial denaturing step at 95°C for 5 minutes, followed by 30 cycles of 
denaturing at 95°C for 30 seconds, annealing at 54°C for 30 seconds, and extension at 72°C 
for 90 seconds. A final extension step was done at 72°C for 10 minutes to complete any 
partial amplicons. 
 
Construction of DB-TDP-43 by Gateway Cloning 
Gateway cloning is an efficient method to transfer DNA between two plasmids. 
The cloning consists of two steps, BP and LR reaction. In the BP reaction, the full length 
TDP-43 gene (PCR product with attB sites) was inserted into the pDONR223 (Donor 
vector) in the presence of BP Clonase, to develop a TDP-43 entry clone. An entry clone is 
then used to transfer the gene into different destination vectors. In order to confirm that 
TDP-43 was successfully inserted into the pDONR223, restriction digestion was done 
using EcoRV and XhoI. In the LR reaction, the TDP-43 gene was transferred from entry 
clone to a destination vector (DB empty vector) in the presence of LR clonase, to develop 
a DB-TDP-43 clone (TDP-43 is fused with DNA binding domain). The clone was 
confirmed by restriction digestion (XcmI) and sequencing. 
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Transformation of Yeast 
DB-TDP-43 was transformed into the yeast strain Y8930 (haploid mating type ) 
using a one-step transformation protocol. Briefly, freshly grown cells were resuspended 
with DNA in 100ul transformation buffer (100uM lithium acetate, 100uM DDT and 40% 
PEG), incubated at 42°C for 40 minutes, with a brief vortex every 10 minutes. The selective 
marker for DB-TDP-43 construct is Leu2, so the cells were plated onto Leucine dropout 
plates and grown at 30°C. Transformants usually appear in 3 days. 
 
Site directed mutagenesis 
Site directed mutagenesis was used to introduce mutations to TDP-43 on entry 
vector of pDONR223. Sense and antisense primers for 5 different TDP-43 mutants 
(D169G, Q331K, G298S, A315T and M337V) are shown on table 2. The reaction consisted 
of an initial denaturing step at 95°C for 30 sec, followed by 18 cycles of denaturing at 95°C 
for 30 seconds, annealing at 55°C for 1 minute and elongation at 68°C for 3 minutes. The 
final extension step was done at 68 °C for 10 minutes. The methylated and non-mutated 
parental DNA was then digested using Dpn I. The newly synthesized DNA with TDP-43 
mutations was then transformed into DH5α Escherichia coli cells and was plated on 
LB/spectinomycin plates. The colony was picked from each mutant and miniprep was 
performed (Qiagen). The mutations were confirmed by sequencing.  
 
 
 
 
 
 
 
 
 
 
 
15 
 
 
 
 
 
 
 
Table 2: Primers for site directed mutagenesis. Below is the table showing forward and reverse primers 
used in site directed mutagenesis. 
 
Mutant Forward primers Reverse primers 
D169G 5'GTCACACCATCGTCCACC 
TATCATATGTCGCTGT3’ 
5'ACAGCGACATATGATAGGTGGA
CGATGGTGTGAC3' 
Q331K 5'CCCCAACTGCTCTTTAG 
TGCTGCCTGGGC 3' 
5'GCCCAGGCAGCACTAAAGAGCA
GTTGGGG 3' 
G298S 5'TGATTGTTTCCCAAACTA
GCTCCACCCCCTCTG 3' 
5'CAGAGGGGGTGGAGCTAGTTTG
GGAAACAATCA 3' 
A315T 5'GGATTAATGCTGAACGTA
CCAAAGTTCATCCCACCA 3' 
5'TGGTGGGATGAACTTTGGTACGT
TCAGCATTAATCC 3' 
M337V 5'GGCTAACATGCCCACCAT 
ACCCCAACTGCTC 3' 
5'GAGCAGTTGGGGTATGGTGGGC
ATGTTAGCC 3' 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16 
Y2H 
Y2H is a widely used genetic method to identify protein-protein interactions. In 
Y2H, the transcription factor GAL4 is split into two domains, the activation domain (AD) 
and DNA binding domain (DB). The AD was fused with an unknown gene from cDNA 
library and transformed into the yeast strain Y8800 (haploid mating type a). The DB fused 
with TDP-43 plasmid was transformed into yeast strain Y8930 (haploid mating type α). 
When AD and DB are separate, transcription of the reporter gene does not occur (Figure 
5a). However, when prey protein (Y) interacts with the protein of interest (TDP43), the 
interaction will bring AD and DB to close proximity, resulting in transcription of the 
reporter gene (Figure 5b). The reporter gene used in my screenings was HIS3, which 
promotes growth on plates lacking histidine. The two yeast (Y8800 and Y8930) were 
mated for four hours to bring AD and DB constructs together. A 1:10,000 dilution was 
plated on glucose plates lacking leucine and tryptophan (LT-) to determine the number of 
clones screened. The rest of the cells were plated on glucose plates lacking leucine, 
tryptophan and histidine (LTH-) to identify potentially positive interactions.  
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Figure 5: Y2H screening. The DNA binding domain is fused with TDP-43 (DB-TDP-43) and unknown 
protein (Y) from the cDNA library is fused with activation domain (Y-AD). a. When DB-TDP-43 are separate 
from AD-Y, HIS reporter gene is not activated and no transcription occurs. b. When DB-TDP-43 interacts 
with Y-AD, the transcription of the HIS reporter gene will be activated, so the strain will grow in the absence 
of histidine.  
 
 
 
a 
b 
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Colony PCR 
Colony PCR is used to amplify unknown gene (Y) from AD constructs. In this 
method, colony that contains AD-Y was lysed and directly used as a template. Forward 
and reverse primers was designed based on the vector sequences that flank unknown gene 
Y (Figure 6). The colonies (positive hits) from Y2H were lysed in lysis buffer (0.1M 
NaPO4 buffer of pH 7.4 mixed with 2.5 mg/ml Zymolase) for 30 minutes. PCR was 
performed using forward primer (ADF) 5’ CGCGTTTGGAATCACTAC AGGG-3’ and 
reverse primer (ADDB reverse) 5’ CTGGCAAGGTAGACAAGCC 3’. The conditions for 
PCR include an initial denaturing step at 95°C for 5 minutes, followed by 35 cycles of 
denaturing at 95°C for 30 seconds, annealing at 54°C for 30 seconds and extension at 72°C 
for 5 minutes. The final extension step was done at 72°C for 10 minutes to complete any 
partial amplicons. Finally, gel electrophoresis was performed to detect the amplified DNA. 
The DNA was purified using gel DNA recovery kit (Zymoclean).  
 
Gap Repair    
Gap repair is used to remake the AD constructs identified from Y2H screening. 
When the linearized AD vector and colony PCR product (Y) (that was amplified based on 
the sequences of the AD vector) were transformed into yeast Y8800, homologous 
recombination will happen and the AD construct will be remade with the amplified gene 
inserted into it (Figure 7). The circular AD vector was linearized by Sma I restriction 
enzyme at 25°C for 3 hours. Saccharomyces (Y8800) was grown overnight in YPD 
medium and the PCR product obtained from colony PCR was transformed with linearized 
AD into Y8800. The transformed cells were plated on tryptophan dropout plates.  
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 Figure 6: Colony PCR. A figure shows the amplification of unknown gene (Y) from a yeast colony using 
forward and reverse primers that are complementary to the AD vector. 
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Figure 7: Gap repair. A schematic diagram indicates that when the colony PCR product (Y) and linearized 
AD vector are transformed into yeast Y8800, since the two share the same sequences (as indicated in green 
and red) at the ends, homologous recombination will happen and AD vector will be successfully remade with 
the gene (Y) inserted into it.  
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Hits Verification 
The colonies obtained from gap repair were mated with DB-TDP-43 on YPD plates 
for 4 hours. The mated colonies were spotted on LT- and LTH- plates. The growth on LTH- 
plates confirms the positive interactions. The corresponding PCR product were sent for 
sequencing, and the results were subjected to a BLAST search against the NCBI database  
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RESULTS 
 
Amplification of TDP-43 template 
TDP-43 is a 414 amino acid DNA/RNA binding protein with a molecular mass of 
43 KDa. Before performing Y2H and analyzing the putative interactions with TDP-43, I 
amplified the template of TDP-43 in order to make the DB-TDP-43 construct. The template 
was amplified with a PCR reaction and was electrophoresed on a 1% agarose gel. As shown 
in Figure 8, PCR product is ~ 1.3 Kb, the expected size of TDP-43.  
 
Construction of DB-TDP-43 by Gateway Cloning (BP reaction)  
In order to make DB-TDP-43, gateway cloning was performed. It consists of two 
step reactions, a BP and a LR reaction. In the BP reaction, the DNA template (TDP-43) 
was successfully transferred into the entry vector (pDONR223) (Figure 9). The entry clone 
was verified by restriction digestion using EcoRV and XhoI. The expected 1.2 kb and 2.7 
kb confirms that TDP-43 was successfully inserted into the Entry clone. 
                 In the LR reaction, TDP-43 was successfully transferred into the destination 
vector (DB empty vector) from the entry clone in the presence of LR clonase (Figure 10). 
In order to confirm that the gene was successfully inserted into DB vector, restriction 
digestion was performed using a XcmI restriction enzyme. On gel electrophoresis the size 
of the bands observed was 3.6kb and 6kb as expected.  
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Figure 8: Gel electrophoresis of PCR product of TDP-43. Gel Electrophoresis of the TDP-43 showing 
the band size of ~1.3 kb. On the left is the ladder showing 0.5 to 1.5 kb sizes. 
 
 
 
 
 
 
 
 
 
 
 
1.3kb 
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Figure 9: BP reaction (Gateway cloning). The PCR product of TDP-43 flanked with attB sites was 
inserted into the pDONR223 vector in presence of BP Clonase II enzyme with two flanking recombination 
sequences called “attP 1” and “attP 2”, to construct “TDP-43 Entry clone”.  
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Figure 10: LR reaction (Gateway cloning) - The TDP-43 DNA fragment was transferred from entry vector 
to destination vector (DB empty vector) in the presence of LR clonase enzyme to construct TDP-43 
destination vector (DB-TDP-43).   
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Construction of mutant TDP-43 by site directed mutagenesis 
Five mutants of TDP-43 chosen for this project are D169G, Q331K (sporadic), 
G298S, A315T and M337V (Familial). To identify the binding partners of mutated TDP-
43, we introduced each of these mutations into TDP-43 on the entry vector pDONR223 by 
site-directed mutagenesis. All the mutated gene of TDP-43 was later transferred to the 
destination vector by LR reaction of gateway cloning. The constructed expression clone of 
each mutant (DB- DI69G, DB-Q331K, DB-G298S, DB-A315T and DB-M337V) was then 
confirmed by restriction digestion with PvuII. On gel electrophoresis, 4.1 and 5.5 kb was 
observed as expected. All DB constructs of mutant TDP-43 were ultimately confirmed by 
sequencing.  
 
Y2H screening 
Y2H is a genetic approach to identify protein-protein interactions. In Y2H, when 
WT DB-TDP-43 interacted with the AD-cDNA libraries of brain and fetal brain proteins, 
colony growth was observed on LTH. The colonies appeared on LT- indicates the number 
of genes screened. Y2H was also repeated for each of the five missense mutants of TDP-
43 (D169G, Q331K, G298S, A315T and M337V) using libraries from both human brain 
and human fetal brain. The results from sreening using cDNA library of human brain were 
shown in Figure 11 and summarized in Table 3. The plate pictures from screening using 
cDNA library of fetal brain looked similar to Figure 11 (data not shown). The results were 
summarized in Table 3 
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Figure 11: Y2H screening using cDNA library from human brain. The figure shows colony growth on 
LT- plates (left) and LTH- (right) when Y2H was performed with DB-WT and five mutants of TDP-43 
(D169G, Q331K, G298S, A315T and M337V) as baits. The number of colonies on LT- plates indicates total 
number of genes screened. as indicated, ~1 million clones was screened from each WT and mutant TDP-43. 
The number of colonies on LTH- plates probably indicates total number of positive hits.  
LTH- LT- (104) 
WT 
    D169G 
 Q331K 
   G298S 
 A315T 
M337V 
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Table 3: Y2H Screening of WT and mutant TDP-43. This table shows the results of Y2H screening of 
wild type and mutants of TDP-43 i.e. D169G, Q331K, G298S, A315T and M337V, using cDNA libraries of 
human brain and fetal brain. The number of colonies on LT- plates indicated the number of genes screened. 
The number of colonies on LTH- plates were the number of potential interactions. The number of picked 
colonies indicated the number of interactions (big colonies) selected for further analysis.  
 
cDNA 
libraries 
Mutants Screened 
(10^4) (LT-) 
Interactions 
(LTH-) 
Picked 
colonies 
1. Brain 
cDNA 
library 
Wild Type 
 D169G 
 Q331K   
G298S  
A315T  
M337V 
 100 
 122 
96 
118 
95 
76 
400 
62 
50 
58 
45 
40 
127 
45 
30 
45 
30 
15 
2. Fetal 
Brain cDNA 
library 
Wild Type 
D169G 
Q331K  
G298S 
 A315T  
M337V 
80 
136 
154 
160 
122 
120 
250 
50 
33 
30 
45  
70 
90 
15 
5 
10 
15 
40 
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Identification of AD-Y interactors by Colony PCR  
To confirm that the colonies contained genes encoding proteins that interact with 
TDP-43, colony PCR was performed to identify all the interactors of wild type and mutant 
TDP-43. The encoding sequence of unknown gene ‘Y’ was retrieved by PCR amplification 
directly from yeast colonies. The amplified sequence was electrophoresed on agarose gel. 
Several PCR products showed identical sizes, indicating that they might represent same 
sequences. PCR products of unique sizes were selected for next step (Figure 12). 
 
Gap Repair to re-make AD-Y constructs identified from Y2H screening  
 Gap repair was performed to reconstruct each AD-Y plasmid. The unique PCR product 
from colony PCR above has the end sequences matching with AD vector. When it’s 
transformed together with linearized AD vector into Y8800 (mating type a), homologous 
recombination happens, bringing the gene and AD vector together to remake the AD 
constructs. Colony growth on Trp- plates indicates successful recombination. Figure 13 
represents gap repair of one hit from Y2H screening of wild type and mutant (D169G, 
Q331K, G298S, A315T, and M337V) TDP-43. The same procedure was repeated for all 
other hits.    
 
Hits verification 
Y8800 containing AD-Y reconstructed from gap repair was mated with Y8930 containing 
DB-TDP-43. i.e. Y8800 containing AD-Y from Y2H screening for WT TDP-43 were 
mated with Y8930 containing DB-TDP-43 (Figure 14). Similarly Y8800 containing AD-
Y from Y2H screening for mutant TDP-43 were mated with Y8930 containing its 
corresponding DB mutants. The mated strains were then spotted onto LT- and LTH- plates. 
 
30 
The growth on indicating the successful mating to bring the two constructs together. The 
growth on LTH- plates confirms positive interactions. Figure 14 shows representative 
results from WT TDP-43 and its mutant A315T and M337V.  
 
Assembling and Verification of hits 
All the verified interactors from WT and mutant TDP-43 were assembled and 
summarized in Table 4. A total of 131 proteins were identified from Y2H screenings of 
WT and mutant TDP-43 together. The summary of the hits are shown in table 5. 
To determine similarity and differences of binding partners of WT and mutant 
TDP-43, the positive hits identified from Y2H of one bait protein (i.e. WT TDP-43) will 
be crosschecked for their potential interactions with other bait protein (i.e. mutant TDP-
43). Before doing this, I checked the interactions of the hits with their corresponding baits 
first. Only one hit from Y2H screening of WT TDP-43 still showed interaction with TDP-
43. All other hits (130 out 131) did not show interactions with their corresponding baits 
any more (Figure 15). Since all of 131 hits were previously confirmed, this result is 
completely unexpected. 
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Figure 12: Colony PCR product of hits identified from Y2H screenings of wild type and mutant TDP-
43. Total 467 hits from Y2H screening of WT and mutant TDP-43 (Table 3)  were selected for colony PCR. 
These gel pictures illustrate some of the colony PCR products from Y2H screening of wild type TDP-43 and 
five different mutants (D169G, Q331K, G298S, A315T, M337V). Size of  the DNA bands was determined 
by 1 kb ladder (NEB) on the left.  
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Figure 13: AD constructs remade by gap repair. The figure above shows yeast strain Y8800 that contain 
AD constructs re-made through gap repair. One representative hit from Y2H screening of WT and mutant 
TDP-43 (D169G, Q331K, G298S, A315T and M337V) was shown.  
 
 
 
 
 
 
 
 
 
 
Wild type TDP-43 D169G 
Q331K G298S 
A315T M337V 
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Figure 14: Verification of Y2H hits from WT and mutant (A315T and M337V) TDP-43. Yeast strains 
with DB-WT and mutant DB-TDP-43 (A315T and M337V) were mated with strain containing AD 
constructs, re-made by gap repair. Cells after mating were spotted onto LT- and LTH- plates. Growth on LT- 
plates indicates successful mating to bring two constructs together. Growth on LTH- plates indicates positive 
interactions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LT- (Mutant A315T and M337V 
TDP-43) 
LTH- (Mutant A315T and M337V 
(TDP-43) 
                   LT- (WT-TDP-43) LTH- (WT-TDP-43) 
 
34 
Table 4: Summary of Hits. The table below shows the verified hits from both wild type and mutant TDP-
43. The name of the colony (in my stock plates for my own record), cDNA library used, bait of WT or mutant 
TDP-43, size of colony PCR product is indicated for each of the hits.  
 
 
 
Name of the colony cDNA library Wild type or Mutant Band sizes
B1 Brain Wild type (WT) 1.7 kb
B3 Brain Wild type (WT) 3.0kb
B4 Brain Wild type (WT) 3.2kb
B5 Brain Wild type (WT) 3.0kb
B7 Brain Wild type (WT) 2.0kb
B8 Brain Wild type (WT) 1.5kb
B9 Brain Wild type (WT) 0.7kb
B10 Brain Wild type (WT) 1.0kb
B15 Brain Wild type (WT) 0.8kb
B17 Brain Wild type (WT) 1.6kb
B63 Brain Wild type (WT) 1.7kb
B64 Brain Wild type (WT) 2.3kb
B76A Brain Wild type (WT) 0.9kb
B76B Brain Wild type (WT) 2.3kb
B78 Brain Wild type (WT) 5kb
B91 Brain Wild type (WT) 4kb
B93 Brain Wild type (WT) 1.2kb
B97 Brain Wild type (WT) 0.6kb
B99 Brain Wild type (WT) 0.4kb
FB1 Fetal brain Wild type (WT) 2.1kb
FB3 Fetal brain Wild type (WT) 1.7kb
FB5 Fetal brain Wild type (WT) 1.3kb
FB11 Fetal brain Wild type (WT) 0.9kb
FB12 Fetal brain Wild type (WT) 0.8kb
FB13 Fetal brain Wild type (WT) 1.5kb
FB16 Fetal brain Wild type (WT) 0.5kb
FB17 Fetal brain Wild type (WT) 2.0kb
FB18 Fetal brain Wild type (WT) 1.0kb
FB35 Fetal brain Wild type (WT) 1.2kb
FB36 Fetal brain Wild type (WT) 2.3kb
FB53 Fetal brain Wild type (WT) 0.7kb
FB59 Fetal brain Wild type (WT) 1.3kb
DB1 Brain Mutant D169G 2kb
DB3 Brain Mutant D169G 1.5kb
DB5 Brain Mutant D169G 1.4kb
DB7 Brain Mutant D169G 1.8kb
DB11 Brain Mutant D169G 0.9kb
DB13 Brain Mutant D169G 2.5kb
DB17 Brain Mutant D169G 1.3kb
DB18 Brain Mutant D169G 2.2kb
DB19a Brain Mutant D169G 2.3kb
DB21 Brain Mutant D169G 1.6kb
DB24 Brain Mutant D169G 5kb
DB26 Brain Mutant D169G 3kb
DB28 Brain Mutant D169G 4kb
DB29 Brain Mutant D169G 0.7kb
DFB2 Fetal brain Mutant D169G 0.4kb
DFB3 Fetal brain Mutant D169G 3kb
DFB4 Fetal brain Mutant D169G 2.8kb
DFB8 Fetal brain Mutant D169G 2kb
DFB11 Fetal brain Mutant D169G 0.6kb
DFB12 Fetal brain Mutant D169G 0.3kb
QB1 Brain Mutant Q331K 1.6kb
QB4 Brain Mutant Q331K 2kb
QB5 Brain Mutant Q331K 5kb
QB7 Brain Mutant Q331K 2.1kb
QB11 Brain Mutant Q331K 1.7kb
QB12 Brain Mutant Q331K 2.4kb
QB13 Brain Mutant Q331K 2.3kb
QB14 Brain Mutant Q331K 2.6kb
QB17 Brain Mutant Q331K 0.7kb
QB20 Brain Mutant Q331K 1.5kb
QB22 Brain Mutant Q331K 0.8kb
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QB23 Brain Mutant Q331K 1.8kb
QB27 Brain Mutant Q331K 0.9kb
QB28 Brain Mutant Q331K 0.5kb
QB29 Brain Mutant Q331K 2.7kb
QFB2 Fetal brain Mutant Q331K 1.5kb
QFB3 Fetal brain Mutant Q331K 1.7kb
QFB4a Fetal brain Mutant Q331K 0.6kb
QFB5 Fetal brain Mutant Q331K 2kb
GB2 Brain Mutant G298S 0.5kb
GB4 Brain Mutant G298S 1.2kb
GB6 Brain Mutant G298S 2.0kb
GB8 Brain Mutant G298S 2.5kb
GB12 Brain Mutant G298S 1.6kb
GB13 Brain Mutant G298S 0.8kb
GB16 Brain Mutant G298S 2.0kb
GB17 Brain Mutant G298S 0.7kb
GB19 Brain Mutant G298S 1.3kb
GB28 Brain Mutant G298S 3.0kb
GB30 Brain Mutant G298S 1.3kb
GFB1 Fetal brain Mutant G298S 0.7kb
GFB2 Fetal brain Mutant G298S 1.8kb
GFB3a Fetal brain Mutant G298S 4.0kb
GFB3b Fetal brain Mutant G298S 1.2kb
GFB4 Fetal brain Mutant G298S 2.0kb
GFB7 Fetal brain Mutant G298S 3.0kb
GFB8 Fetal brain Mutant G298S 0.8kb
AB1 Brain Mutant A315T 1.1kb
AB2 Brain Mutant A315T 0.8kb
AB3 Brain Mutant A315T 2.0kb
AB4 Brain Mutant A315T 1.0kb
AB5 Brain Mutant A315T 1.5kb
AB6 Brain Mutant A315T 0.9kb
AB8 Brain Mutant A315T 3.0kb
AB9 Brain Mutant A315T 1.6kb
AB15 Brain Mutant A315T 0.5kb
AB19 Brain Mutant A315T 2.7kb
AB23 Brain Mutant A315T 1.3kb
AB24 Brain Mutant A315T 1.9kb
AB35 Brain Mutant A315T 1.4kb
AB36 Brain Mutant A315T 2.2kb
AFB1b Fetal brain Mutant A315T 1.3kb
AFB2 Fetal brain Mutant A315T 5kb
AFB4 Fetal brain Mutant A315T 1.3kb
AFB6 Fetal brain Mutant A315T 1.4kb
AFB7 Fetal brain Mutant A315T 3.0kb
AFB8 Fetal brain Mutant A315T 0.4kb
AFB9 Fetal brain Mutant A315T 4.0kb
AFB12 Fetal brain Mutant A315T 2.0kb
AFB14 Fetal brain Mutant A315T 2.2kb
MB1 Brain Mutant M337V 1.3kb
MB6 Brain Mutant M337V 0.7kb
MB7 Brain Mutant M337V 2.0kb
MB9 Brain Mutant M337V 0.8kb
MB14 Brain Mutant M337V 3.0kb
MB15 Brain Mutant M337V 0.4kb
MFB1 Fetal brain Mutant M337V 3.0kb
MFB3 Fetal brain Mutant M337V 1.3kb
MFB4 Fetal brain Mutant M337V 2.8kb
MFB5 Fetal brain Mutant M337V 1.4kb
MFB6 Fetal brain Mutant M337V 2.0kb
MFB10 Fetal brain Mutant M337V 0.9kb
MFB11 Fetal brain Mutant M337V 1.8kb
MFB16 Fetal brain Mutant M337V 1.5kb
MFB17a Fetal brain Mutant M337V 4.0kb
MFB21 Fetal brain Mutant M337V 5kb
MFB25 Fetal brain Mutant M337V 1.7kb
MFB27 Fetal brain Mutant M337V 2.1kb
MFB31 Fetal brain Mutant M337V 1.0kb
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Table 5: Number of confirmed hits. These are the number of positive interactions of WT and mutant TDP-
43 screened from cDNA libraries of brain and fetal brain. All these interactions have been confirmed by gap 
repair. Out of the total 131 interactions of both WT and mutant TDP-43, the number identified from brain vs 
fetal brain is: 19 vs 13 for WT, 14 vs 6 for D169G, 15 vs 4 for Q311K, 11 vs 7 for G298S, 14 vs 9 for A315T, 
and 6 vs 13 for M337V respectively.  
 
      
          Bait 
WT D169G Q331K G298S A315T M337V 
 
Brain 
19 14 15 11 14 6 
Fetal 
Brain 
 
13 
 
6 
 
4 
 
7 
 
9 
 
13 
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Figure 15: Verification of hits. Strains containing 131 AD constructs (confirmed hits) were mated with 
yeast strain containing the corresponding DB-TDP-43 constructs, of which the hits were initially identified. 
Cells after mating were spotted onto LT- plates (not shown) and LTH- plates. only one strong growth was 
observed on LTH- plates (highlighted),indicating a postive interaction. Unexpectedly, 130 out 131 prevously 
confirmed hits did not show intereaction with their corresponding bait: 1-18 G298S, 19-41 A315T, 42-60 
M337V, 61-92 WT TDP-43, 93-112 D169G, 113- 131 Q331K.  
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Reverification of hits  
                   Surprisingly, upon verification, only one hit showed a positive 
interaction, as shown  in Figure 15. To figure out possible reason, I revived all the hits from 
glycerol stock (stored after Y2H screening), and retested the growth. Besides the LT- and 
LTH- plates previouly used, I added 3AT to LTH- plates. 3-AT, an inhibitor of HIS3 
reporter gene activity, prevents growth from background activity (no interaction between 
bait and prey), so that it significantly decrease false positives. In addition, three control 
strains were added to the plates to indicate strong, weak and no interaction respectively. 
After this test, only 17 out of 131 hits previouly identified still showed growth, as 
highlighted on LTH-+3AT plates  in Figure 16, indicating most of the growth previously 
seen on LTH- plates may be from background activity of reporter gene, not actual 
interaction between prey and my bait (WT and mutant TDP-43). 8 out of the 178 can further 
be validated through gap repair. Among these 8, 4 are from the screening using WT TDP-
43 as bait (3 from library of fetal brain, and 1 from that of brain). Other four is from cDNA 
library of brain, one each using D169G, G298S, A315T and M337V as bait. Interestingly, 
none of hits for mutant TDP-43 are from cDNA library of fetal brain. 
Crosscheck (Comparison) 
                    In order to find similarities and differences between WT and mutant TDP-43 
interactions, yeast strains (Y8800) containing 8 hits (1-8 in Figure 17) were mated with a 
yeast strain 8930 containing DB constructs of WT and mutant TDP-43 (D169G, Q331K, 
G298S, A315T and M337V). As shown in Figure 17, hit #2 strongly interacts with WT 
and mutant TDP-43. The other 7 hits showed strong interactions with WT and M337V, 
weak interactions with G298S and A315T, and very weak interactions with D169G and 
Q331K.  
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Sequencing of hits 
 
                     The colony PCR product from 8 confirmed hits was run on gel (Figure 18). 
the same size of DNA bands suggests that all 8 hits may be the same gene. Sequencing 
confirmed it was the case. The sequences in hit #1-8 are all from PICK1 gene, encoding a 
protein named as protein interacting with C-kinase 1.  
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Figure 16: Reverification of Hits. Total 131 hits identified from Y2H screening of WT and mutant TDP-43 
were revived from glycerol stock, and spotted onto A. LT- plates. Cell growth on LT- indicate it contains 
contructs of both bait and prey. B. LTH- plates. Cell growth on LTH- plates indicates potentially the positive 
interactions between the bait and prey. C. LTH- +3AT plates. 3AT acts as an inhibitor for HIS repoter gene, 
decreasing cell growth from background activity of report gene, so in this condition, strong and weak 
interactions are usually easier to distinguish. 17  colonies showed growth on LTH- +3AT  plates indicating 
positive interaction (black boxes). The bottom row marked with pink box are the 3 control strains indicating 
no interaction, weak interaction and strong interaction respectively (from left to right). 
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Figure 17: Crosscheck (Comparison). The 8 hits (yeast strain with AD construct re-made through gap 
repair) were mated with yeast strains containing DB construct of WT and five different mutants. Cells were 
then spotted onto LT- plate (A) and LTH-+3AT plate (B) Growth on LT- plates indicates successful mating 
to bring the bait and prey together. Growth on LTH-+3AT indicates positive interactions. Three control 
strains indicating no interaction, weak interaction and strong interaction (from left to right), were also 
included on each plate (marked by pink boxes). 
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Figure 18: Electrophoresis of colony PCR products from 8 hits. The gel picture above shows DNA 
amplified from 8 hits. All of them showed the same band size of ~ 2kb, indicating they are might be from the 
same gene. L: 1 kb ladder. 
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DISCUSSION 
The goal of this project was to identify the novel interactions with WT and mutant 
TDP-43 and to compare their binding partners. PICK1 was the only protein that was 
identified.  Although PICK1 interacts with both WT and mutant TDP43, interestingly, it 
has weaker binding affinity to most mutant TDP-43.  
 
Advantages and limitations of Y2H 
Y2H is powerful genetic method for analysis of known, as well as identification of 
unknown, interactions within a living yeast cell (Brückner et al., 2009). Moreover weak 
and strong interactions can be easily detected by this method efficiently. The aim of this 
study was to screen human adult brain and human fetal brain cDNA libraries for interactors 
of WT and mutant TDP-43 using Y2H. I initially identified 131 potential interactors from 
cDNA libraries of adult human brain and fetal brain. As mentioned in table 5, out of 131 
interactions, 19 interactions of WT TDP-43 were from the cDNA library of brain and 13 
hits were from the cDNA library of fetal brain. The potentially positive hits of all the five 
mutants from cDNA library of brain were 60 and from the cDNA library of fetal brain was 
39, respectively. Usually cDNA libraries consists of both highly expressed genes and low 
expressed genes. In order to decrease and equalize the expression of highly expressed 
genes, the cDNA libraries are normalized (Shcheglov et al., 2007). The cDNA libraries 
used in this project were not normalized. Instead I made sure ~1 million clones were 
screened, statistically that covers the whole genome.  
Only 8 hits were considered real at the end from 131 hits initially identified. 
Because all initial 131 hits were supposed to be confirmed already by gap repair, this result 
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was very surprising and completely unexpected to us. The possible reason is that the growth 
initially seen on LTH- and later after gap repair was not from true activation of the reporter 
gene through interaction of bait and prey, instead it may have been from background 
activity of the reporter gene (Sobhanifar, 2003; Walhout and Mark, 2001). This is 
particularly a problem when the plates are incubated too long, leading to the growth of 
false positives. This issue, however, can be easily corrected if control strains are included 
to indicate the growth of no interactions, weak interactions, and strong interactions. 
Unfortunately, it was not what I did in my initial experiments. This is a good lesson to 
learn. 
When all the 8 hits in figure 16 were crosschecked with DB constructs of WT and 
mutant TDP-43 (D169G, Q331K, G298S, A315T and M337V), although sequences of all 
the hits corresponded to the same gene PICK1, variability  was observed in Hit 2. While 
other 7 hits showed weak interaction with mutant G298S and A315T, and even weaker or 
no interaction with mutant D169G and Q331K, hit #2 interacted strongly with WT and all 
mutant TDP43. The possible reason for this variablity can be that fragment of the gene in 
hit 2 is different from that of other hits. The weaker interactions of mutant TDP-43 also 
indicate that these regions of TDP-43 are important for its binding to PICK1.  Further 
studies are needed to determine whether the weaker interaction of mutant TDP-43 with 
PICK1 is physiologically relevant. 
It is worthy to note that my Y2H screening of TDP-43 did not identify any binding 
partners previously studied using other methods. This may not be necessarily surprising. 
Although different methods are usually complementary, they are uniquely able to identify 
only certain protein-protein interactions. It is interesting to know that only 20% of the 
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interactions are similar with different methods of screening (Ito et al., 2001).  Of course, 
another possibility is that I did not saturate my screening, though this was not expected 
statistically.   
 
PICK1 structure and function 
PICK1 is a membrane protein and is ubiquitously expressed in all the tissues, 
especially in brain and testis (Xu and Xia, 2006). PICK1 is a mutli-domain protein, 
including a N-terminal acidic region (NAR), PSD-95/DlgA/ZO-1 (PDZ), Bin-
Amphiphysin-Rvs (BAR) domain and C-terminal acidic amino acid region (CAR) (Li et 
al., 2016). NAR binds with Ca2+ and regulates the interaction of GluA2 subunit of AMPA 
(α amino- 3- hydroxyl-5-methylisoxazole- 4 propionic acid) with PICK1 during long term 
depression (Hanely and Hanely, 2005). The PDZ domain of PICK1 interacts with several 
membrane proteins such as acid sensing ion channels (ASICs). ASICs are involved in 
neuromodulation and pain perception in sensory neurons. Phosphorylation of protein 
kinase and Interaction of PICK1 regulates ASICs activity (Baron et al, 2002). Interestingly, 
the PDZ domain of PICK1 also interacts with PDZ binding domain of the coxsackie B 
virus and adenovirus receptor (Excoffon et al., 2004). BAR domain interacts with lipid 
molecules and regulates expression of PICK1 binding partners (Xu and Xia, 2006). The 
CAR domain, a negatively charged acidic region, hinders the lipid binding activity of BAR 
domain by decreasing positive charges of the BAR domain (Jin, et al., 2006).  
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Role of PICK1 in diseases 
PICK1 is known to interact with many proteins and is involved in various diseases 
(Figure 19) (Li et al., 2016). The Table 6 shows some of the binding partners of PICK1.  
These interactions help in regulating activity of enzymes and ion channels, and the 
trafficking of various transporters.  
 
Interaction between PICK1 and TDP-43 
According to previous studies, the glycine rich domain of TDP-43 (Sephton et al., 
2013) and PDZ domain of PICK1 are commonly involved in protein-protein interactions 
(Bolia et al., 2012). Are these two domains involved in their interaction with each other? I 
compared sequences of the 8 hits (Figure 16) from my screening, 1 to 700 nucleotides of 
PICK1 were the common sequences in all the hits that showed interaction with TDP-43. 
These 700 nucleotides correspond to the NAR domain and more than half of the PDZ 
domain of PICK1. Since TDP-43 does not contain any known PDZ binding motif, it is less 
likely that PDZ domain of PICK1 is directly involved. Thus I speculate that PICK1 
interacts with TDP-43 through its NAR domain, probably with C terminal glycine rich 
domain of TDP-43. A future experiment can be performed to identify the specific domains 
that are involved in the interaction. 
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Figure 19: Role of PICK1 in various disorders. This is the schematic diagram showing the number of 
neurological and non-neurological disorders in which PICK1 is involved (Li et. al, 2016).  
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Table 6: Known protein interactions of PICK1. The table below shows the list of some of the proteins that 
interact with PICK1. 
 
Gene Protein References 
αPKC Protein kinase Cα Staudinger et al., 1995 
EphR Ephrin receptors Torres et al., 1998 
mGluR7a Metabotropic glutamate receptors Boudin et al., 2000 
Arf1 Arfaptin1 Takeya et al., 2000 
ErbB2 Erythroblastic leukemia viral oncogene Jaulin et al., 2001 
PrRP Prolactin-releasing peptide receptor Lin et al., 2001 
DAT Dopamine transporter Torres et al., 2001 
Kalirin-7 Oncoprotein Penzes et al., 2001 
ASICs Acid-sensing ion channels Baron et al., 2002 
BNaC1  Ion channel family Duggan et al., 2002 
Netrin1 Netrin receptor Williams et al., 2003 
CAR  Coxsackie B virus and adenovirus 
receptor 
Excoffon et al., 2004 
Phosphoinositide Lipid molecule Jin et al., 2006 
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Role of PICK1 in ALS  
PICK1 involvement in various neurodegenerative diseases is particularly 
interesting. The focus of my project is ALS, a neurodegenerative disease caused by loss of 
motor neurons (Rothstein, 2009). The cause of ALS is not yet known but glutamate toxicity 
is the common feature of this disease in human and animal models (Bosch et al., 2006). 
The three binding partners of PICK1: AMPA receptor, GLT-1b and serine racemase (SRR) 
act as key factors of glutamate mediated toxicity (Bassan et al., 2009; Dev et al., 1999; 
Fujii et al., 2006). And these binding partners are potentially involved in ALS (Table 7). 
In 2013, Focant et al. demonstrated that abnormal expression of PICK1 in astrocytes leads 
to development of ALS in rats. These data indicate how the interaction of TDP-43 and 
PICK1 may play an important role in pathogenesis of ALS.  
 
Conclusion 
PICK1 and TDP-43 are both reported to be involved in ALS, the interaction 
between the two may play an important role in normal and diseased conditions. Further 
studies need to be proceeded to determine the biological functions of this interaction, 
particularly whether the weaker interaction of mutant TDP43 with PICK1 is 
physiologically relevant. 
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Table 7: Known protein interactions of PICK1 involved in ALS. This table shows the three binding 
partners of PICK1 and their implications in ALS 
 
PICK1 Partners 
 
Role in ALS References 
 
AMPA receptor subunit GluR2 
 
Calcium permeability – defect in 
mRNA process in sporadic ALS 
 
Gardner et al., 
2005 
 
Glutamate receptor(GLT-1b) 
 
Increased expression of GLT-1b in 
sporadic and familial ALS 
 
Howland et al., 
2002 
 
Serine Racemase 
 
D serine production in sporadic 
and familial ALS 
 
Sasabe et 
al.,2007 
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